CY1122194T1 - Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης - Google Patents

Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης

Info

Publication number
CY1122194T1
CY1122194T1 CY20191101002T CY191101002T CY1122194T1 CY 1122194 T1 CY1122194 T1 CY 1122194T1 CY 20191101002 T CY20191101002 T CY 20191101002T CY 191101002 T CY191101002 T CY 191101002T CY 1122194 T1 CY1122194 T1 CY 1122194T1
Authority
CY
Cyprus
Prior art keywords
oxopyridin
difluorophenyl
ethyl
amino
alanine
Prior art date
Application number
CY20191101002T
Other languages
English (en)
Inventor
Stéphane PINTAT
Stephen John Davies
David Charles Festus Moffat
Original Assignee
Macrophage Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218640.9A external-priority patent/GB201218640D0/en
Priority claimed from GB201306881A external-priority patent/GB201306881D0/en
Application filed by Macrophage Pharma Limited filed Critical Macrophage Pharma Limited
Publication of CY1122194T1 publication Critical patent/CY1122194T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει έναν μεταβολίτη που παράγεται από την υδρόλυση της εστερικής ένωσης Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2Η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ)-L-αλανινικότερτ-βουτύλιο, ο οποίος είναι χρήσιμος για την αναστολή της δράσης ενός ενζύμου κινάση p38 MAP.
CY20191101002T 2012-10-17 2019-09-23 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης CY1122194T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1218640.9A GB201218640D0 (en) 2012-10-17 2012-10-17 Chemical compounds
GB201306881A GB201306881D0 (en) 2013-04-16 2013-04-16 Chemical compounds
PCT/GB2013/052689 WO2014060742A1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
EP13783363.8A EP2909175B1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Publications (1)

Publication Number Publication Date
CY1122194T1 true CY1122194T1 (el) 2020-11-25

Family

ID=49488610

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100756T CY1119080T1 (el) 2012-10-17 2017-07-17 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανιnικο tert-boytyλio ή ενα αλας, υδριτης ή διαλυτωμα αυτου
CY20191101002T CY1122194T1 (el) 2012-10-17 2019-09-23 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100756T CY1119080T1 (el) 2012-10-17 2017-07-17 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανιnικο tert-boytyλio ή ενα αλας, υδριτης ή διαλυτωμα αυτου

Country Status (27)

Country Link
US (3) US9388136B2 (el)
EP (2) EP2909175B1 (el)
JP (2) JP6260975B2 (el)
KR (1) KR102164536B1 (el)
CN (2) CN106496106B (el)
AU (1) AU2013333636B2 (el)
BR (1) BR112015008167B1 (el)
CA (1) CA2888928C (el)
CY (2) CY1119080T1 (el)
DK (2) DK3222616T3 (el)
ES (2) ES2743768T3 (el)
HK (1) HK1211028A1 (el)
HR (2) HRP20171320T1 (el)
HU (2) HUE035525T2 (el)
IL (2) IL237863B (el)
IN (1) IN2015DN02721A (el)
LT (1) LT3222616T (el)
MX (1) MX364782B (el)
NZ (1) NZ706717A (el)
PL (2) PL3222616T3 (el)
PT (2) PT2909175T (el)
RS (2) RS59458B1 (el)
RU (1) RU2676329C2 (el)
SG (2) SG10201708166SA (el)
SI (2) SI2909175T1 (el)
WO (1) WO2014060742A1 (el)
ZA (1) ZA201501958B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708166SA (en) * 2012-10-17 2017-11-29 Macrophage Pharma Ltd Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
PL212910B1 (pl) 2002-02-12 2012-12-31 Smithkline Beecham Corp Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
JP2005526068A (ja) 2002-03-14 2005-09-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗炎症剤としての単環式アロイルピリジノン類
EP1964577B1 (en) 2005-05-05 2016-04-13 GlaxoSmithKline Intellectual Property Development Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608855D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase enzymes
WO2007129040A1 (en) 2006-05-04 2007-11-15 Chroma Therapeutics Ltd. p38 MAP KINASE INHIBITORS
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2665736A1 (en) 2006-10-25 2008-05-02 Chroma Therapeutics Ltd. Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
WO2008053182A1 (en) 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS
ATE524454T1 (de) 2006-11-01 2011-09-15 Chroma Therapeutics Ltd Inhibitoren von ikk-beta serinthreoninproteinkinase
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
EP2245012B1 (en) * 2008-02-29 2013-07-03 Chroma Therapeutics Limited Inhibitors of p38 map kinase
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
BRPI0822522A2 (pt) 2008-04-23 2018-06-05 Chroma Therapeutics Ltd Inibidores da proteína quinase ikk-beta serina- treonina
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
WO2009130475A1 (en) 2008-04-26 2009-10-29 Chroma Therapeutics Ltd., Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SG10201708166SA (en) * 2012-10-17 2017-11-29 Macrophage Pharma Ltd Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof

Also Published As

Publication number Publication date
JP2018048160A (ja) 2018-03-29
LT3222616T (lt) 2019-09-10
PL3222616T3 (pl) 2019-12-31
US20150246883A1 (en) 2015-09-03
PT3222616T (pt) 2019-09-26
US10370332B2 (en) 2019-08-06
RS56184B1 (sr) 2017-11-30
MX2015004368A (es) 2015-06-10
BR112015008167A2 (pt) 2017-07-04
SG11201502515VA (en) 2015-05-28
HUE046132T2 (hu) 2020-02-28
PL2909175T3 (pl) 2017-10-31
US20160297760A1 (en) 2016-10-13
CY1119080T1 (el) 2018-01-10
HK1211028A1 (en) 2016-05-13
JP6464244B2 (ja) 2019-02-06
NZ706717A (en) 2018-02-23
JP2015534974A (ja) 2015-12-07
CA2888928C (en) 2020-05-26
EP3222616B1 (en) 2019-07-17
BR112015008167B1 (pt) 2020-11-17
ZA201501958B (en) 2016-01-27
SI3222616T1 (sl) 2019-10-30
EP2909175A1 (en) 2015-08-26
RU2015115213A (ru) 2016-12-10
IL237863B (en) 2018-06-28
US9896417B2 (en) 2018-02-20
RS59458B1 (sr) 2019-11-29
RU2676329C2 (ru) 2018-12-28
SG10201708166SA (en) 2017-11-29
CN104781235A (zh) 2015-07-15
IN2015DN02721A (el) 2015-09-04
IL256560B (en) 2019-07-31
EP2909175B1 (en) 2017-06-07
ES2635240T3 (es) 2017-10-03
JP6260975B2 (ja) 2018-01-17
CN106496106A (zh) 2017-03-15
MX364782B (es) 2019-05-07
HRP20191874T1 (hr) 2020-01-10
DK3222616T3 (da) 2019-08-19
AU2013333636A1 (en) 2015-04-09
KR20150067376A (ko) 2015-06-17
HUE035525T2 (en) 2018-05-28
AU2013333636B2 (en) 2017-11-23
SI2909175T1 (sl) 2017-08-31
US9388136B2 (en) 2016-07-12
WO2014060742A1 (en) 2014-04-24
EP3222616A1 (en) 2017-09-27
DK2909175T3 (en) 2017-08-14
CN106496106B (zh) 2019-05-10
ES2743768T3 (es) 2020-02-20
HRP20171320T1 (hr) 2017-10-20
PT2909175T (pt) 2017-09-13
CN104781235B (zh) 2016-12-21
CA2888928A1 (en) 2014-04-24
IL256560A (en) 2018-02-28
KR102164536B1 (ko) 2020-10-12
US20180127371A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
CY1122176T1 (el) Αλατα ενος αναστολεα κινασης υποδοχεα επιδερμικου αυξητικου παραγοντα
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
CY1118212T1 (el) Παραγοντες οι οποιοι τροποποιουν την s1p
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
SMT201500037B (it) Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti
BR112013033511A2 (pt) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6 - pentahidroxihexil)ethóxi)fenil)butil)carbamimidoil) pirazina-2-carboxamida
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201790715A1 (ru) Новые соединения
EA201200741A1 (ru) Способ получения этексилата дабигатрана
NZ715838A (en) Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
NZ724645A (en) Pde10 inhibitors and related compositions and methods
UY34486A (es) Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
EA201591349A1 (ru) Способ получения вортиоксетина
CY1122194T1 (el) Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης
EA201101152A1 (ru) Лиофилизированный дабигатран
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
ZA201604932B (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA201400939A1 (ru) Способ получения медетомидина с использованием хлорацетона
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.